Recommendations for Optimizing Tuberculosis Treatment: Therapeutic Drug Monitoring, Pharmacogenetics, and Nutritional Status Considerations

키워드

참고문헌 (82)

1. "Global tuberculosis report 2016. WHO/HTM/TB/2015.22" (2016)[URL]
2. 신홍준, "Treatment of Drug Susceptible Pulmonary Tuberculosis", Tuberculosis and Respiratory Diseases, 78(3), pp.161~167 (2015), 대한결핵및호흡기학회
3. Horsburgh CR Jr, "Treatment of tuberculosis", N Engl J Med, 373, pp.2149~2160 (2015)
4. Wing Wai Yew, "Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?", The Korean Journal of Internal Medicine, 31(1), pp.15~29 (2016), 대한내과학회[DOI]
5. Marra F, "Adverse drug reactions associated with first-line anti-tuberculosis drug regimens", Int J Tuberc Lung Dis, 11, pp.868~875 (2007)
6. Lv X, "Adverse reactions due to directly observed treatment strategy therapy in chinese tuberculosis patients: a prospective study", PLoS One, 8, pp.e65037~ (2013)
7. Munro SA, "Patient adherence to tuberculosis treatment: a systematic review of qualitative research", PLoS Med, 4, pp.e238~ (2007)
8. Yew WW, "Antituberculosis drugs and hepatotoxicity", Respirology, 11, pp.699~707 (2006)
9. Pasipanodya JG, "Serum drug concentrations predictive of pulmonary tuberculosis outcomes", J Infect Dis, 208, pp.1464~1473 (2013)
10. Mah A, "Serum drug concentrations of INH and RMP predict 2-month sputum culture results in tuberculosis patients", Int J Tuberc Lung Dis, 19, pp.210~215 (2015)
11. Blumberg HM, "American Thoracic Society", Centers for Disease Control and Prevention, Am J Respir Crit Care Med, pp.2003, 167[DOI]
12. "Treatment of tuberculosis: guidelines for national programmes, WHO/HTM/TB/2009.420" (2009)[URL]
13. Satyaraddi A, "Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity", Int J Tuberc Lung Dis, 18, pp.188~195 (2014)
14. Pasipanodya JG, "Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy", Clin Infect Dis, 55, pp.169~177 (2012)
15. Srivastava S, "Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability", J Infect Dis, 204, pp.1951~1959 (2011)
16. Alsultan A, "Therapeutic drug monitoring in the treatment of tuberculosis: an update", Drugs, 74, pp.839~854 (2014)
17. Reynolds J, "Understanding pharmacokinetics to improve tuberculosis treatment outcome", Expert Opin Drug Metab Toxicol, 10, pp.813~823 (2014)
18. Sotgiu G, "Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment", Int J Infect Dis, 32, pp.101~104 (2015)
19. Ma Q, "Pharmacogenetics, pharmacogenomics, and individualized medicine", Pharmacol Rev, 63, pp.437~459 (2011)
20. Pirazzoli A, "Pharmacogenetics and pharmacogenomics: are they still promising?", Pharmacol Res, 49, pp.357~361 (2004)
21. Sun F, "Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis", Int J Tuberc Lung Dis, 12, pp.994~1002 (2008)
22. Wang PY, "NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis", Int J Tuberc Lung Dis, 16, pp.589~595 (2012)
23. Li C, "GSTM1 and GSTT1 genetic polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity: an updated meta-analysis", Eur J Clin Microbiol Infect Dis, 32, pp.859~868 (2013)
24. Oshikoya KA, "A systematic review of pharmacokinetics studies in children with protein-energy malnutrition", Eur J Clin Pharmacol, 66, pp.1025~1035 (2010)
25. Jeremiah K, "Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV", Antimicrob Agents Chemother, 58, pp.3468~3474 (2014)
26. Hatsuda K, "The impact of nutritional state on the duration of sputum positivity of Mycobacterium tuberculosis", Int J Tuberc Lung Dis, 19, pp.1369~1375 (2015)
27. Zeng J, "A serum vitamin D level <25nmol", l pose high tuberculosis risk: a meta-analysis, 2015, pp.10, e0126014~
28. Pareek M, "Vitamin D deficiency and TB disease phenotype", Thorax, 70, pp.1171~1180 (2015)
29. Junaid K, "Genotype-independent association between profound vitamin D deficiency and delayed sputum smear conversion in pulmonary tuberculosis", BMC Infect Dis, 15, pp.275~ (2015)
30. Kwon YS, "Tuberculosis: clinical trials and new drugregimens", Curr Opin Pulm Med, 20, pp.280~286 (2014)
31. Kwon YS, "Synthetic investigational new drugs for the treatment of tuberculosis", Expert Opin Investig Drugs, 25, pp.183~193 (2016)
32. Wilby KJ, "Review of evidence for measuring drug concentrations of first-line antitubercular agents in adults", Clin Pharmacokinet, 53, pp.873~890 (2014)
33. Peloquin CA, "Therapeutic drug monitoring in the treatment of tuberculosis", Drugs, 62, pp.2169~2183 (2002)
34. "A practical handbook on the pharmacovigilance of medicines used in the treatment of tuberculosis" (2012)[URL]
35. Magis-Escurra C, "Therapeutic drug monitoring in the treatment of tuberculosis patients", Pulm Pharmacol Ther, 25, pp.83~86 (2012)
36. Burtis CA, "Tietz Textbook of Clinical Chemistry and Molecular Diagnostics" (2012), Elsevier Health Sciences
37. Heysell SK, "Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA", Emerg Infect Dis, 16, pp.1546~1553 (2010)
38. Perwitasari DA, "Pharmacogenetics of isoniazid-induced hepatotoxicity", Drug Metab Rev, 47, pp.222~228 (2015)
39. Sprague DA, "Limited-sampling strategies for anti-infective agents: systematic review", Can J Hosp Pharm, 62, pp.392~401 (2009)
40. Wang L, "Genomics and drug response", N Engl J Med, 364, pp.1144~1153 (2011)
41. Matsumoto T, "Future of pharmacogenetics-based therapy for tuberculosis", Pharmacogenomics, 15, pp.601~607 (2014)
42. Selinski S, "Improvements in algorithms for phenotype inference: the NAT2 example", Curr Drug Metab, 15, pp.233~249 (2014)
43. Caudle KE, "Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process", Curr Drug Metab, 15, pp.209~217 (2014)
44. Whirl-Carrillo M, "Pharmacogenomics knowledge for personalized medicine", Clin Pharmacol Ther, 92, pp.414~417 (2012)
45. McDonagh EM, "PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2", Pharmacogenet Genomics, 24, pp.409~425 (2014)
46. Azuma J, "NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy", Eur J Clin Pharmacol, 69, pp.1091~1101 (2013)
47. Jung JA, "A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis", Drug Des Devel Ther, 9, pp.5433~5438 (2015)
48. "Guideline: Nutritional care and support for patients with tuberculosis" (2013)[URL]
49. Hood ML, "A narrative review of recent progress in understanding the relationship between tuberculosis and protein energy malnutrition", Eur J Clin Nutr, 67, pp.1122~1128 (2013)
50. Grobler L, "Nutritional supplements for people being treated for active tuberculosis", Cochrane Database Syst Rev, pp.Cd006086~ (2016)
51. WHO, "IMAI district clinician manual: Hospital care for adolescents and adults", World Health Oragnization, ~ (2011)
52. McPherson RA, "Henry’s Clinical Diagnosis and Management by Laboratory Methods" (2011), Elsevier Health Sciences
53. Choi R, "Serum concentrations of trace elements in patients with tuberculosis and its association with treatment outcome", Nutrients, 7, pp.5969~5981 (2015)
54. Vilcheze C, "Mycobacterium tuberculosis is extraordinarily sensitive to killing by a vitamin C-induced Fenton reaction", Nat Commun, 4, pp.1881~ (2013)
55. Daley P, "Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial", Lancet Infect Dis, 15, pp.528~534 (2015)
56. Cegielski P, "Tuberculosis and vitamin D: what’s the rest of the story?", Lancet Infect Dis, 15, pp.489~490 (2015)
57. Koo HK, "Vitamin D deficiency and changes in serum vitamin D levels with treatment among tuberculosis patients in South Korea", Respirology, 17, pp.808~813 (2012)
58. Choi CJ, "Relationship between serum 25-hydroxyvitamin D and lung function among Korean adults in Korea National Health and Nutrition Examination Survey (KNHANES), 2008-2010", J Clin Endocrinol Metab, 98, pp.1703~1710 (2013)
59. Kim JH, "Low serum 25-hydroxyvitamin D level: an independent risk factor for tuberculosis?", Clin Nutr, 33, pp.1081~1086 (2014)
60. Hong JY, "Association between vitamin D deficiency and tuberculosis in a Korean population", Int J Tuberc Lung Dis, 18, pp.73~78 (2014)
61. Lexicomp, "Drug Information Handbook" (2014), Lexi-Comp
62. Peloquin CA, "Using therapeutic drug monitoring to dose the antimycobacterial drugs", Clin Chest Med, 18, pp.79~87 (1997)
63. Kurose K, "Population differences in major functional polymorphisms of pharmacokinetics", pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development, 2012, pp.27, 9~54
64. Kang TS, "Comparison of genetic polymorphisms of the NAT2 gene between Korean and four other ethnic groups", J Clin Pharm Ther, 34, pp.709~718 (2009)
65. Lee SY, "Complete sequencing of a genetic polymorphism in NAT2 in the Korean population", Clin Chem, 48, pp.775~777 (2002)
66. Lee KM, "N-acetyltransferase (NAT1, NAT2) and glutathione S-transferase (GSTM1, GSTT1) polymorphisms in breast cancer", Cancer Lett, 196, pp.179~186 (2003)
67. Bertrand J, "Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia", J Infect Dis, 209, pp.399~408 (2014)
68. Garte S, "Metabolic gene polymorphism frequencies in control populations", Cancer Epidemiol Biomarkers Prev, 10, pp.1239~1248 (2001)
69. Sabbagh A, "Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history", BMC Genet, 9, pp.21~ (2008)
70. Sabbagh A, "Arylamine N-acetyltrans ferase 2 (NAT2) genetic diversity and traditional subsistence: a worldwide population survey", PLoS One, 6, pp.e18507~ (2011)
71. Villamor E, "Effects of vitamin a supplementation on immune responses and correlation with clinical outcomes", Clin Microbiol Rev, 18, pp.446~464 (2005)
72. Gupta KB, "Tuberculosis and nutrition", Lung India, 26, pp.9~16 (2009)
73. Verrall AJ, "Early clearance of Mycobacterium tuberculosis: a new frontier in prevention", Immunology, 141, pp.506~513 (2014)
74. Madebo T, "Circulating antioxidants and lipid peroxidation products in untreated tuberculosis patients in Ethiopia", Am J Clin Nutr, 78, pp.117~122 (2003)
75. Rodriguez GM, "Metallobiology of Tuberculosis", Microbiol Spectr, 2 (2014)
76. Minchella PA, "Complex anemia in tuberculosis: the need to consider causes and timing when designing interventions", Clin Infect Dis, 60, pp.764~772 (2015)
77. Hood MI, "Nutritional immunity: transition metals at the pathogen-host interface", Nat Rev Microbiol, 10, pp.525~537 (2012)
78. Shi X, "Copper homeostasis in Mycobacterium tuberculosis", Metallomics, 7, pp.929~934 (2015)
79. Neyrolles O, "Mycobacteria, metals, and the macrophage", Immunol Rev, 264, pp.249~263 (2015)
80. Arthur JR, "Selenium in the immune system", J Nutr, 133, pp.1457s~1459s (2003)
81. Hoffman AE, "Co(II) and Cu(II) pyrophosphate complexes have selectivity and potency against Mycobacteria including Mycobacterium tuberculosis", Eur J Med Chem, 70, pp.589~593 (2013)
82. Perez-Guzman C, "A cholesterol-rich diet accelerates bacteriologic sterilization in pulmonary tuberculosis", Chest, 127, pp.643~651 (2005)

관련 논문AI추천